Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, has announced updated clinical data from its ongoing Phase 1/2 ABILITY-1 study evaluating MDNA11 in patients with advanced solid tumors. The results were presented at the European Society of Medical Oncology (ESMO) Immuno-Oncology Congress 2025. MDNA11, described as a long-acting 'beta-enhanced not-alpha' interleukin-2 (IL-2) super-agonist, is being tested both as a monotherapy and in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). In monotherapy expansion cohorts, patients who had progressed on immune checkpoint inhibitors demonstrated an objective response rate $(ORR)$ of 42% and a disease control rate (DCR) of 83%. Specifically, the ORR was 38% in melanoma and 22% in microsatellite instability-high (MSI-H) cancers, with corresponding DCRs of 75% and 78%. The company plans to share further data from the ABILITY-1 study, as well as from the upcoming NEO-CYT trial and early studies with MDNA113, in the coming months. A webinar discussing the updated results is being hosted by the Medicenna management team and clinical investigators, with a replay available on the company's website.